FDA approves expanded use of Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant to include individuals 27 through 45 years old

October 5, 2018 – The U.S. Food and Drug Administration today approved a supplemental application for Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant, expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine. “Today’s approval represents an important … (leggi tutto)